Cell Mediated Reaction, Influenza Vaccine Allergy
Conditions
Keywords
influenza vaccine, immune response, dynamic changes
Brief summary
An observational clinical study will be performed in subjects aged 12-60 years old to describe the dynamic changes of humoral immune/cellular immunity after vaccination of influenza vaccine, and to discuss the role of different antibodies against influenza virus infection, and to look for possible factors related to side effects with the vaccine.
Detailed description
A randomized clinical trial will be conducted to describe immune response of seasonal influenza virus vaccine in a single center in China. 200 subjects aged 18-60 years will be enrolled under the premise of informed consent and receive one dose of vaccine. All vaccinations will be done by specific study personnel, who do not take part in the assessment of safety or immunogenicity. Adverse events will be recorded after vaccination and blood samples were collected at 0,7,14,28 days for antibody detection and split vaccine neutralizing antibody detection, determination of cellular immune function in the same time. The clinical program approved by the ethics committee will be performed by the researchers independently. Inspectors designated by the sponsor will take meticulous on-site audits to ensure the safety specifications during the whole process of research.
Interventions
None listed
Sponsors
Centers for Disease Control and Prevention, China
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* aged 12-60 years old * male or non-pregnant female * volunteers * clinically healthy as determined by: medical history inquiring and physical examination * provide written informed consents before joining the trial
Exclusion criteria
* infected with Influenza A virus subtype H1N1(2009), * vaccinated with seasonal influenza vaccine, * allergic to any ingredient of vaccine, * autoimmune disease or immunodeficiency, * active malignancy, * bleeding disorder, * seizure disorder, * Guillain-Barre Syndrome, * treatment with cytotoxic or immunosuppressive drugs within the past 6 months, * receipt of blood products within the past 3 months, * administration of any other investigational research agents or live attenuated vaccine within 30 days, * administration of subunit or inactivated vaccines within 14 days, * axillary temperature over 37.0℃ at the time of vaccination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the dynamic changes of humoral immune/cellular immunity after vaccination of influenza vaccine | one year |
Outcome results
None listed